The publication in the Journal of Inflammation Research entitled “Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial” highlights – within a clinical study – the legitimacy of Dr Sigman’s intuition and the validity of MLS® Laser Therapy on patients suffering from interstitial pneumonia caused by COVID-19.
The recent publication in the Journal of Inflammation Research reports that the effects on the patients were measured through blood tests, chest X-rays, oxygenation monitoring, and through validated scores – subjective and objective – for pneumonia. The results actually showed that patients undergoing MLS® Laser Therapy:
.1 had a rapid recovery;
.2 showed an improvement in pulmonary indices (score: SMART-COP, BCRSS, RALE and CAP);
.3 did not need intensive care or mechanical ventilation support;
.4 did not report any posthumous consequences 5 months after treatment.